Online Program Home
My Program

Abstract Details

Activity Number: 263
Type: Contributed
Date/Time: Monday, August 1, 2016 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract #319450
Title: A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations in the Presence of a Baseline Covariate
Author(s): Sungjin Kim* and Mourad Tighiouart and Marcio Diniz
Companies: and Cedars-Sinai Medical Center and Cedars-Sinai Medical Center
Keywords: Cancer Phase I trials ; Maximum tolerated dose ; Escalation with overdose control ; Drug combination ; Continuous dose ; Baseline covariate
Abstract:

We describe a Bayesian adaptive design for estimating the maximum tolerated dose curve as a function of a baseline covariate using two cytotoxic agents. Parametric models are used to describe the relationship between the doses, baseline covariate, and the probability of dose limiting toxicity (DLT). Trial design proceeds by treating cohorts of two patients simultaneously using escalation with overdose control, where at each stage of the trial, we seek a dose of one agent using the current posterior distribution of the MTD of this agent given the current dose of the other agent and the next patient's baseline covariate value. At the end of the trial, we estimate MTD curves as functions of Bayes estimates of the model parameters. We evaluate design operating characteristics in terms of safety of the trial and percent of dose recommendation at dose combination neighborhoods around the true MTD by comparing the design that uses the covariate to the one that ignores the baseline characteristic. The methodology is further adapted to the case of a pre-specified discrete set of dose combinations.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

 
 
Copyright © American Statistical Association